Lyell Appoints Richard Sherry, M D , as Senior Vice President, TIL Specialist and Clinical Lead prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Reports $72.6M of Cash on Hand to Fund Clinical Programs and Extend Operations into 2023 Conference Call Today at 4:30 p.m. (ET)
News provided by
Share this article
Share this article
ROCKVILLE, Md., March 4, 2021 /PRNewswire/ Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020.
05 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. The full text announcement is contained below and can be accessed on Achilles website at: https://achillestx.com/news . Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of Syncona Limited. These statements and forecasts involve risk and uncertainty because they relate t
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials
Phase I/IIa CHIRON and THETIS Trials
London, UK 5 February 2021 - Achilles Therapeutics ( Achilles or the Company ), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/IIa CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. In this review of the first six patients dosed with the Company s Clonal Neoantigen Targeting T cell therapy (cNeTs), the overall tolerability profile was generally similar to that of standard tumor-infiltrating lymphocyte (TIL) products that have not been enriched for cNeT reactivities, with the lymphodepletion regimen acc
The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.
Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments in patients suffering respiratory distress as a result of COVID-19 infection.
Inhaled Ampion specifically targets inflammation in the lung. Researchers are hopeful that the use of the drug stands to improve the clinical outcome for patients with respiratory distress due to COVID-19.